Myriad Genetics (MYGN) Getting Somewhat Positive Media Coverage, Report Finds

Media headlines about Myriad Genetics (NASDAQ:MYGN) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Myriad Genetics earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the company an impact score of 48.1406389698711 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:

Several equities analysts recently issued reports on MYGN shares. Barclays reduced their price objective on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Wednesday, August 9th. Jefferies Group reaffirmed a “hold” rating and set a $23.00 price objective (up from $21.00) on shares of Myriad Genetics in a report on Thursday, August 10th. Zacks Investment Research cut Myriad Genetics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. BidaskClub raised Myriad Genetics from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Finally, Cowen reaffirmed a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $28.10.

Myriad Genetics (MYGN) opened at $33.53 on Tuesday. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $37.30. The firm has a market capitalization of $2,341.72, a price-to-earnings ratio of 31.03, a PEG ratio of 2.14 and a beta of 0.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The company had revenue of $190.20 million during the quarter, compared to analysts’ expectations of $183.52 million. During the same period in the previous year, the firm posted $0.23 earnings per share. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. equities research analysts anticipate that Myriad Genetics will post 1.05 EPS for the current year.

In other news, insider Alexander Ford sold 3,031 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $31.64, for a total value of $95,900.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2017/12/05/myriad-genetics-mygn-getting-somewhat-positive-media-coverage-report-finds.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Insider Buying and Selling by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply